Breaking News

Lloyds Reaches $370 Million Settlement With Regulators Over Libor
Tweet TWEET

Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE

Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal
PLOS ONE

Pluristem's Cells Were Reported to Serve as Highly Effective "Off the Shelf"
Therapy to Treat Acute Radiation Syndrome and Radiation Induced Bone Marrow
Failure in Animals

HAIFA, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that preclinical results for its Placental eXpanded
(PLX) RAD cells in the treatment of bone marrow disease have been published in
peer reviewed journal PLOS ONE.

A study titled "Mitigation of lethal radiation syndrome in mice by
intramuscular injection of 3D cultured adherent human placental stromal cells"
was published on June 18th in the open access journal PLOS ONE
(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066549).
This animal study on acute radiation syndrome (ARS) was performed by Professor
Raphael Gorodetsky and his team at the Biotechnology and Radiobiology
Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center,
Jerusalem in collaboration and the support of Pluristem Therapeutics. The
findings of the published study suggest that intramuscular treatment with
Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf"
therapy to mitigate ARS.

The treatment of intramuscular injection of PLX-RAD cells increased the
survival of 7.7Gy irradiated mice from about 27% to about 98% (P<0.0001). The
treated mice regained their weight significantly faster than the few survivors
of the controls. The treatment stimulated extensive hematopoietic stem cells
(HSC) proliferation to enable the speedy recovery of the radiation induced
depleted bone marrow with parallel increase the number of circulating white
blood cells, red blood cells and platelets. The number of CD45+/SCA1+
hematopoietic progenitor cells within the fast recovering population of
nucleated bone marrow cells in the irradiated mice was also elevated in the
mice treated with PLX-RAD cells.

Prof. Raphael Gorodetsky commented: "The intramuscular injection of PLX-RAD
significantly increased the survival of animals exposed to high lethal doses
of total body irradiation even when treatment was delayed by more than 24 hrs
after exposure. Therefore, our study points for the application of such
treatments in scenarios of nuclear accidents involving numerous casualties
also in remote disaster areas."

"The current publication which follows our announcement from 07 September
2011, further supports Pluristem's finding that the combination of the
Placenta as a rich cell source and our propriety 3D manufacturing platform may
lead to new product and therapies for unmet needs and will increase the level
of awareness for our technology in the medical community," stated Pluristem
Chairman and CEO Zami Aberman.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

About Hadassah University Medical Center

Hadassah is a state-of-the-art medical center incorporating all medical and
surgical sub-specialties, with a tertiary care referral hospital at Ein Kerem
and a community hospital on Mt. Scopus; Hadassah Hospitals have 850 physicians
and Academic University Affiliated researchers, 1,940 nurses, 1,020
paramedical and support staff,1,200 support stuff, 1,200 beds, 31 operating
theaters, 9 intensive care units and over 120 outpatient clinics treating over
1 million people a year from all over Israel and from neighboring countries.
Hadassah's Hospitals conduct more than half the medical research in Israel.
The flagship of Hadassah, the Women's Zionist Organization of America, is the
main supporter of the Hadassah Medical Center.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss that the
findings of the published study suggest that intramuscular treatment with
Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf"
therapy to mitigate ARS, or thatthe study points for the application of such
treatments in scenarios of nuclear accidents involving numerous casualties
also in remote disaster areas, or our finding that the combination of the
Placenta as a rich cell source and our propriety 3D manufacturing platform may
lead to new product and therapies for unmet needs, or that the study published
in PLOS ONE will increase the level of awareness for our technology in the
medical community, we are using forward-looking statements. These
forward-looking statements and their implications are based on the current
expectations only of the management of Pluristem and the involved academic
researchers, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo